An anonymous director reports
AVICANNA EXPANDS RHO PHYTO FORMULARY WITH THE INTRODUCTION OF CANNABIGEROL (CBG) PRODUCTS INTO THE CANADIAN MARKET
Avicanna Inc. will be expanding its RHO Phyto formulary in Canada with cannabigerol (CBG) formulations into medical and adult-use channels across Canada.
Avicanna expands its trusted RHO Phyto brand to include several CBG formulations which will be made available across various medical cannabis channels, including Medical Cannabis by Shoppers, and adult-use channels beginning with its two listings on the Ontario Cannabis Store (OCS) in Q3 2022. As the Canadian cannabis market continues to expand, Avicanna is leveraging its research and development capabilities to deliver differentiated medical and wellness products, including rare cannabinoid formulations into established commercial channels. The initial CBG formulations will include:
- RHO Phyto Rapid Act THC CBG spray: A combination of THC (tetrahydrocannabinol) and CBG in a lemon-mint flavoured spray that utilizes Avicanna's sublingual delivery technology to provide fast onset;
- RHO Phyto Micro Drop THC CBG CBD oil: A combination of THC, CBG and cannabidiol in a blood-orange-flavoured oil which utilizes Avicanna's inverted emulsion technology to provide enhanced absorption and shelf-life stability;
- RHO Phyto CBG Transdermal relief gel: A combination of CBG and CBD in a fast-absorbing, water-based gel. The gel employs Avicanna's proven deep tissue technology and combines cannabinoids with synergistic natural ingredients and terpenes, including menthol and beta-caryophyllene.
CBG is a rare and non-psychoactive cannabinoid which acts as the precursor to other more commonly known cannabinoids, including CBD, THC and CBG, interacts with several receptors throughout the skin and body that are known to be targets for inflammation, infection and pain, as well as neurological and mood-related disorders. Specifically, modern research has investigated CBG and its potential role in analgesia, anti-inflammation and anti-bacterial, and for its neuroprotective properties. In particular, the use of CBG in topical formulations provides local applications for various conditions such as arthritis, muscle aches and pain due to its anti-inflammatory properties. Additionally, oral applications of CBG such as the Rapid Act sublingual spray or Micro Drops oils are expected to have systematic effects.
Avicanna's research into CBG
Avicanna continues to research the potential therapeutic areas of CBG with its academic and clinical partners, including continuing studies with Thompson River University investigating the potential anti-microbial and anti-inflammatory capabilities of CBG. The results of these studies will provide further guidance toward product development and clinical trials while supporting existing commercial efforts. Moreover, the new additions to the RHO Phyto formulary will be enrolled into Avicanna's medical cannabis real-world evidence trial (MC-RWE) conducted by the University Health Network (UHN). This longitudinal study evaluates the efficacy of medical cannabis on patient-reported outcomes of pain, anxiety, sleep and depression.
Additionally, Avicanna has been conducting research on CBG through its cultivation projects in Colombia where the company has developed a genetic strain of cannabis expressing up to 17 per cent CBG in its biomass. The proprietary genetic has also undergone extraction and is likely the first local source of pure CBG to be available in Colombia from where it has also been exported to the United States and Czech Republic.
About Avicanna Inc.
Avicanna is a commercial-stage international biopharmaceutical company focused on the development, advancement and commercialization of evidence-based cannabinoid products for the global consumer, medical and pharmaceutical market segments. Leading global cannabinoid advancements, the company actively collaborates with renowned Canadian academic and medical institutions in research and commercialization. Avicanna has established an industry-leading scientific platform, including advanced research and development, and clinical development that has led to the commercialization of more than 30 products across its main market segments.
We seek Safe Harbor.
© 2022 Canjex Publishing Ltd. All rights reserved.